首页> 外文期刊>Frontiers in Oncology >Hypofractionated Radiotherapy Dose Scheme and Application of New Techniques Are Associated to a Lower Incidence of Radiation Pneumonitis in Breast Cancer Patients
【24h】

Hypofractionated Radiotherapy Dose Scheme and Application of New Techniques Are Associated to a Lower Incidence of Radiation Pneumonitis in Breast Cancer Patients

机译:低抗疗法的放射治疗剂量方案和新技术的应用与乳腺癌患者的辐射肺炎发病率较低有关

获取原文
           

摘要

Purpose: Radiation pneumonitis (RP) is one of the most severe toxicities experienced by patients with breast cancer after radiotherapy (RT). RT fractionation schemes and techniques for breast cancer have undergone numerous changes over the past decades. This study aimed to investigate the incidence of RP as a function of such changes in patients with breast cancer undergoing RT and to identify dosimetric markers that predict the risk of this adverse event. Methods and Materials: We identified 1,847 women with breast cancer who received adjuvant RT at our institution between 2015 and 2017. The RT technique was individually tailored based on each patient's clinicopathological features. Deep inspiration breath hold technique or prone positioning were used for patients who underwent left whole-breast irradiation for cardiac sparing, while those requiring regional lymph node irradiation underwent volumetric-modulated arc therapy (VMAT). Results: Of 1,847 patients who received RT, 21.2% received the conventional dose scheme, while 78.8% received the hypofractionated dose scheme (mostly 40 Gy in 15 fractions). The median follow-up period was 14.5 months, and the overall RP rate was 2.1%. The irradiated organ at risk was corrected concerning biologically equivalent dose. The ipsilateral lung V _(30) in equivalent dose in 2 Gy (EQD2) was the most significant dosimetric factor associated with RP development. Administering RT using VMAT, and hypofractionated dose scheme significantly reduced ipsilateral lung V _(30). Conclusions: Application of new RT techniques and hypofractionated scheme significantly reduce the ipsilateral lung dose. Our data demonstrated that ipsilateral lung V _(30) in EQD2 is the most relevant dosimetric predictor of RP in patients with breast cancer.
机译:目的:辐射肺炎(RP)是放疗后乳腺癌(RT)后患者最严重的毒性之一。 RT分馏计划和乳腺癌技术在过去几十年中经历了许多变化。本研究旨在探讨RP的发病率作为乳腺癌患者进行的RT患者的函数,并鉴定预测这种不良事件风险的剂量标记。方法和材料:我们确定了1,847名患有乳腺癌的乳腺癌,他们在2015年和2017年之间接受了佐剂RT。基于每位患者的临床病理特征,RT技术单独定制。深度灵感呼吸保持技术或易于定位用于留下全乳房辐照的患者进行心脏熏化的患者,而需要区域淋巴结辐射的那些接受体积调制的ARC疗法(VMAT)。结果:1,847名接受RT,21.2%的患者接受常规剂量方案,而78.8%接受过次级剂量方案(15分数中的40μm)。中位后续期间为14.5个月,总体RP率为2.1%。有关生物学同期的风险的辐照器官纠正。在2GY(EQD2)中的等效剂量中的同侧肺v _(30)是与RP发育相关的最显着的剂量因子。使用VMAT施用RT,次次次次剂量方案显着降低Ipsilidallal肺v _(30)。结论:新型RT技术的应用和低次级的方案显着降低了同侧肺剂量。我们的数据表明,EQD2中的IpsilAtalal肺v _(30)是乳腺癌患者中RP最相关的剂量预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号